William Burnette, MD
Neurology with Special Qualifications in Child Neurology · Nashville, TNNPI 1265579338
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $22,293 of the $22,745 with a category attached, or 98.0%. PTC Therapeutics, Inc. accounts for 79.5% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2021 at $8,988 and has fallen 98.2% since, to $160 in 2024.
Across 15 payments — averaging $1516.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- PTC Therapeutics, Inc.$18K
- Sarepta Therapeutics, Inc.$4K
- Genentech, Inc.$347
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$75
- Catalyst Pharmaceuticals, Inc.$31
Across 88 payments — averaging $4198.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sarepta Therapeutics, Inc.$240K
- Mallinckrodt Enterprises LLC$63K
- Mallinckrodt Hospital Products Inc.$36K
- Pfizer$31K
What the payments were for
- Consulting fees$22,29398%
- Speaking & faculty fees$750%
- Food & beverage$3472%
- Education$310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| PTC Therapeutics, Inc. | 9 | $18,093 |
| Sarepta Therapeutics, Inc. | 1 | $4,200 |
| Genentech, Inc. | 3 | $347 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 1 | $75 |
| Catalyst Pharmaceuticals, Inc. | 1 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,745 in reported general payments places this provider in the 85th percentile of 47 neurology with special qualifications in child neurology providers in Tennessee.
See all neurology with special qualifications in child neurology providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Sodium Phosphate | 11 | $255 |
Paid to pharmacies, not to this prescriber.
Other neurology with special qualifications in child neurology in Nashville
- Jesus Pina GarzaNashville$1.4M
- Jeffrey NeulNashville$127K
- James FryNashville$80K
- Cary FuNashville$19K
- Timothy LivingstonNashville$14K
- Ngochanh VuNashville$4K
- Kaitlin JamesNashville$2K
- Lori JordanNashville$2K
- Michael McCormackNashville$1K
- Robert CarsonNashville$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.